1. HIPK2 as a Novel Regulator of Fibrosis.
- Author
-
Garufi, Alessia, Pistritto, Giuseppa, and D'Orazi, Gabriella
- Subjects
- *
PROTEINS , *DISEASE progression , *EQUIPMENT & supplies , *FIBROBLASTS , *FIBROSIS , *MOLECULAR pathology , *CYTOSKELETAL proteins , *TUMOR markers , *PULMONARY fibrosis , *CELL death - Abstract
Simple Summary: Fibrosis can affect almost every organ and represents an increasing cause of morbidity and mortality worldwide. Despite significant progress in our understanding of the pathobiology of fibrosis, there is still a lack of putative anti-fibrotic targets to be exploited in anti-fibrosis therapies or used as biomarkers of fibrosis progression. The discovery that HIPK2 can control molecular pathways involved in fibrosis has opened a new field of study in both pathophysiology and the treatment of fibrosis. Fibrosis is an unmet medical problem due to a lack of evident biomarkers to help develop efficient targeted therapies. Fibrosis can affect almost every organ and eventually induce organ failure. Homeodomain-interacting protein kinase 2 (HIPK2) is a protein kinase that controls several molecular pathways involved in cell death and development and it has been extensively studied, mainly in the cancer biology field. Recently, a role for HIPK2 has been highlighted in tissue fibrosis. Thus, HIPK2 regulates several pro-fibrotic pathways such as Wnt/β-catenin, TGF-β and Notch involved in renal, pulmonary, liver and cardiac fibrosis. These findings suggest a wider role for HIPK2 in tissue physiopathology and highlight HIPK2 as a promising target for therapeutic purposes in fibrosis. Here, we will summarize the recent studies showing the involvement of HIPK2 as a novel regulator of fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF